AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06479252 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sit-to-Stand Test (STS)
Description: The 30-s and 1-min STS tests are reliable, valid, and responsive tests for measuring functional exercise capacity in patients with lung disease. For the STS tests that are centre-based or supervised remotely, investigators will collect the total number of repetitions on the 30-s and 1-min STS tests, as well as the number and duration of rests within and between tests.
Study NCT06479252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit-to-Stand Test (STS)
Description: The 30-s and 1-min STS tests are reliable, valid, and responsive tests for measuring functional exercise capacity in patients with lung disease. For the STS tests that are centre-based or supervised remotely, investigators will collect the total number of repetitions on the 30-s and 1-min STS tests, as well as the number and duration of rests within and between tests.
Study NCT04713813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise program via hippotherapy mechanical stimulator
Description: Patients were planned to complete hippotherapy exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
Study NCT04713813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic home exercise program
Description: Patients were planned to complete home exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
Study NCT06135779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Lust for Life
Description: A Lust For Life (ALFL) is a universal teacher-led programme which aims to build resilience, increase wellbeing, and enhance emotional literacy of 8-13 year old school children. The programme spans ten 40-minute classes. The ALFL curriculum draws on multiple sources including contemporary positive psychology; traditional, second, and third wave cognitive behaviour therapy (CBT); and developmental, educational, and health psychology. In ALFL children learn the following specific self-regulation skills: naming and rating the intensity of emotions; linking thoughts, feelings and actions; mindfulness; breathing exercises; visualization exercises; progressive muscle relaxation; positive self-talk (gratitude, optimism, and cognitive restructuring); obtaining social support from adults and peers; assertiveness; managing bullying; and using the internet safely. Skills are learned through didactic instruction, video modelling, in-class experiential exercises, and homework practice.
Study NCT06135779 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting List Control
Description: Control group placed on a 12-week waiting list for the A Lust for Life School programme.
Study NCT03125187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium heparin UQ Intravenous drug administration
Description: The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
Study NCT03125187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium heparin FK Intravenous drug administration
Description: The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
Study NCT04875026 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5-fluorouracil 4% (Tolak)
Description: Application of Tolak once daily in the evening for 4 weeks
Study NCT04875026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil 4% (Tolak)
Description: Application of Tolak once daily in the evening for 4 weeks
Study NCT04875026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexeryl
Description: Application of Dexeryl once daily in the morning for 8 weeks
Study NCT06253741 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PARAVERTEBRAL BLOCK
Description: Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes
Study NCT06253741 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RHOMBOID INTERCOSTAL AND SUBSERRATUS PLANE BLOCK
Description: Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes.
Study NCT06253741 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes.
Study NCT05451615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Janus Kinase Inhibitor
Description: One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
Study NCT05451615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
Study NCT05311566 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus Concurrent chemoradiotherapy
Description: Participants will be given intravenous administration of Camrelizumab (200mg，every 2 weeks),Cisplatin(40mg/m²，everyweek) and Radiotherapy. After completing 6\~8weeks of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until disease progression or unacceptable toxicity.
Study NCT05412225 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pre-neoadjuvant radiotherapy (NART) biopsy
Description: Participants will undergo pre-NART core biopsy guided by post-NAC MRI to the area of residual enhancement or to the previously biopsied cancer if no residual enhancement remains
Study NCT05412225 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Description: After biopsy, participants will undergo neoadjuvant radiotherapy/NART
Study NCT05412225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral total mastectomy with axillary lymph node dissection
Description: At 2-6 weeks after completion of NART, participants will undergo unilateral MRM (total mastectomy with axillary lymph node dissection), with resection of all involved breast skin. Skin-sparing mastectomy will not be permitted. All patients will also undergo simultaneous unilateral autologous-based breast reconstruction with DIEP, ms-TRAM, or latissimus dorsi flap.
Study NCT06505551 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCG142
Description: Autologous SCG142 cells infused on Day 0 after completion of lymphedepletion chemotherapy
Study NCT06505551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: for 3 consecutive days
Study NCT06505551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: for 3 consecutive days
Study NCT06645912 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral nutritional supplement
Description: The ONS group received a high-protein ONS providing 18.8 g of protein, 7 g of fat, 28 g of carbohydrates, and 250 calories of energy per 200 mL and medical nutrition therapy. The product is gluten-free and contains lactose, minerals, trace elements, and vitamins . The Control group received only standard nutrition therapy without ONS supplementation.
Study NCT06212765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: to take 1 pod a day for 45 days
Study NCT06212765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-citrulline
Description: to take 1 pod a day for 45 days
Study NCT05809726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymph drainage
Description: one session 20 minutes
Study NCT05809726 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manual lymph drainage
Description: one session 20 minutes
Study NCT05764642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: Ultrasound contrast agent administered intravenously
Study NCT05764642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Definity
Description: Ultrasound contrast agent administered intravenously
Study NCT05764642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Super-resolution ultrasound imaging
Description: Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.
Study NCT05764642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Super-resolution ultrasound imaging
Description: Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.
Study NCT06530498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale
Description: Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale in 9 body regions rated from 0 (no growth of terminal hair) to 4 (extensive hair growth), thus with a score ranging from 0 (the lowest score - no hirsutism) to 36 points (the highest score - the greatest severity of hirsutism)
Study NCT06530498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of the severity of endogenetic alopecia using the visual Ludwig Scale
Description: Visual assessment of baldness on the Ludwig scale from I (least severe baldness) to III (most severe baldness):~Type I - minimal thinning of the mid-line parting in the hair; Type II - gradual thinning and noticeable widening of the mid-line parting in the hair; Type III - Heavy to total thinning of the mid-line
Study NCT05745207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 tablets.
Study NCT05745207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2086 matched placebo tablets.
Study NCT04907331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaxzevria
Description: The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria followed by Comirnaty
Study NCT04907331 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxzevria
Description: The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria followed by Comirnaty
Study NCT04907331 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty
Description: The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria
Study NCT04907331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comirnaty
Description: The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria
Study NCT05614778 — intervention group
Intervention type: OTHER
Intervention: Zoledronic Acid injection, 5mg/100mL
Description: Zoledronic Acid injection, 5mg/100mL
Study NCT05509764 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound score
Description: determination of atelectasis by lung ultrasound score
Study NCT05173506 — intervention group
Intervention type: OTHER
Intervention: Computer decision support for physician
Description: The Child Health Improvement through Computer Automation - Child Neurology (CHICA-CN) system will screen patients for needed services and provide reminders to physicians to provide the needed services.
Study NCT05970783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jincaopian Tablets
Description: Jincaopian Tablets 0.2g tid p.o.
Study NCT05970783 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0.2g tid p.o.
Study NCT05524220 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care with a facemask.
Description: The anesthesia provider will supply oxygen via the closed facemask at 10 liters per minute (LPM)
Study NCT05524220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SuperNO2VA™EtCO2 (Nasal Oxygenating Ventilating Apparatus)
Description: The anesthesia provider will attach the SuperNO2VA™ EtCO2 circuit port to the hyperinflation bag with the oxygen flow rate to 10 L/min. The oxygenation, continuous positive airway pressure, and ventilation of the subject will be done via SuperNO2VA™EtCO2 (Nasal Oxygenating Ventilating Apparatus)
Study NCT05391360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freethiadine tablets(part I)
Description: Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
Study NCT05391360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freethiadine tablets (part II)
Description: once or twice daily for consecutive 28 days
Study NCT05391360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Freethiadine placebo tablets
Description: Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
Study NCT05391360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir tablets
Description: once daily for consecutive 28 days
Study NCT04827134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIUMEQ
Description: TRIUMEQ will be available as fixed dose combination (FDC) dispersible tablets to be administered orally as a dispersion.
Study NCT04827134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOVATO
Description: DOVATO will be available as FDC dispersible tablets to be administered orally as a dispersion.
Study NCT06274164 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalography/Polysomnography (EEG/PSG)
Description: Instigators will determine if subjects are candidate for the procedure. A sleep study records the brain electrical waves, the oxygen level in the blood, heart rate breathing, as well as eye and leg movements. Subjects will need to be admitted overnight for the sleep study.
Study NCT06274164 — intervention group
Intervention type: PROCEDURE
Intervention: Skin Biopsy
Description: A special 3-4 mm (0.12 inches) wide circular tool will be used to remove a small section of skin including deeper layers. A numbing cream or injectable anesthetic (i.e. lidocaine) will be applied to the area before the procedure. Sample will be used to create a cell line. This means that investigators would treat the cells from the sample in a way that allows to grow them in the laboratory. Investigators will then use these cells in research.
Study NCT06274164 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: A single blood sample of 15 cc (not exceeding 3 cc per kg) (\~3 teaspoons) will be collected for metabolomics (biomarker) study. From available family members, same amount of blood will be obtained to use as a control sample.
Study NCT04825860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856 50 mg
Description: Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
Study NCT04825860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856 75 mg
Description: Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
Study NCT04825860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
Study NCT04399239 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AuriNovo
Description: AuriNovo is a patient-specific, biologically natural, supportive base for surgical reconstruction of the external ear (auricle) in people born with microtia Grades II-IV. The construct is a 3D-bioprinted collagen hydrogel scaffold encapsulating the patient's own auricular cartilage cells (chondrocytes). The construct is printed in a size and shape that matches the contralateral ear for implantation into the patient.
Study NCT05501665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT06451328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignosus rhinoceros TM02®
Description: Lignosus rhinoceros TM02®
Study NCT06266702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Oil with Phospholipids
Description: Consumed on white bread
Study NCT06266702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Polyunsaturated Oil Blend
Description: Consumed on white bread
Study NCT05286359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NxTekTM Malaria Pf Plus Rapid Diagnostic Test Device
Description: NxTekTM Malaria Pf/Pv Plus: A sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH) of Plasmodium falciparum(P.f.) on one test line and of pLDH of Plasmodium vivax (P.v.) malaria on a second test line in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.~NxTekTM Malaria Pf Plus: A sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and pLDH on a single test line of Plasmodium falciparum(P.f.) malaria in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.
Study NCT04935840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FertyBiotic Pregnancy
Description: DHA, folic acid, Iodine, iron, Lactobacillus rhamnosus, Lactobacillus reuterii, magnesium, zinc, vitamin D3, Vitamin C, Vitamin E, Group B vitamins and Biotin
Study NCT04935840 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 400 mcg of folic acid
Study NCT05167175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablet
Description: Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily.
Study NCT05167175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Qingkeshu (Abiraterone acetate tablets) 1000 mg should be taken orally once daily.
Study NCT05167175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone tablet
Description: Prednisone Tablets should be taken 5 mg once daily.
Study NCT05267990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Detector Computed Tomography
Description: Coronary angiography calcium score via Multi-Detector Computed Tomography
Study NCT05556564 — intervention group
Intervention type: DRUG
Intervention: observational study
Description: No intervention, observational study
Study NCT04872556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture device
Description: The experiment group would arrange laser acupuncture on day1 and day3 after Taxanes treatment. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
Study NCT04872556 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pseudo-laser acupuncture
Description: The experiment group would arrange Pseudo-laser acupuncture on day1 and day3 after Taxanes treatment. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.